abus团队 abus核衣壳药Sulfamoylbenzamide

newchinabok

Mark J. Murray, Ph.D., President and CEO; formerly of Protiva, Zymogentics, and Xcyte Therapeutics
Patrick T. Higgins, Chief Business Officer; co-founder of OnCore BioPharma; formerly of Pharmasset and Roche
Bruce Cousins, Chief Financial Officer; formerly of Aspreva and Johnson & Johnson
Michael J. Sofia, Ph.D., Chief Scientific Officer; co-founder of OnCore BioPharma; formerly of Pharmasset (inventor of sofosbuvir for hepatitis C), Bristol-Myers Squibb, and Eli Lilly
William T. Symonds, Pharm.D., Chief Development Officer; formerly of Gilead Sciences, Pharmasset (clinical development of sofosbuvir for hepatitis C), and GlaxoSmithKline
Mark Kowalski, MD, Chief Medical Officer; formerly of Gilead Sciences, YM BioSciences, and Viventia Biotechnologies
Peter Lutwyche Ph.D., Chief Technology Officer, formerly of Protiva, QLT, and Inex Pharmaceuticals

newchinabok

马克J.默里，博士，总裁兼首席执行官;原Protiva的，ZymoGenetics公司和Xcyte治疗学
帕特里克·T.希金斯，首席商务官; OnCore生物制药的创始人之一;原Pharmasset和罗氏
布鲁斯·考辛斯，财务总监;以前的Aspreva和强生公司
迈克尔·索菲亚，博士，首席科学官; OnCore生物制药的创始人之一;原Pharmasset（发明者索非布韦的丙型肝炎），百时美施贵宝和礼来的
威廉·T·西蒙兹，药学博士，首席开发官。以前的吉利德科学，Pharmasset（索非布韦的丙肝临床开发）和葛兰素史克
马克·科瓦尔斯基，医学博士，首席医疗官;以前的吉利德科学，生物科学YM和Viventia生物技术
彼得Lutwyche博士，技术总监，原Protiva的，QLT，而INEX制药

newchinabok

http://jvi.asm.org/content/87/12/6931.full

newchinabok

nvr3-778成功，同样期待abus的Sulfamoylbenzamide

newchinabok

DISCUSSION

The therapeutic goals of chronic hepatitis B treatment are to restore normal liver function and prevent the development of cirrhosis, HCC, and liver failure. It has been convincingly demonstrated thus far that inhibition of HBV replication by the currently available antiviral drugs results in significant histological, biochemical, and serological improvement and reduction of HCC mortality and morbidity (60). However, the current antiviral therapeutics fail to resolve HBV infection in the vast majority of treated patients, and the achievement of therapeutic goals in these patients requires long-term, possibly life-long, treatment, which may ultimately fail due to the emergence of drug resistance and/or intolerability from the long-term use of these drugs (10). Hence, there is a pressing need for therapeutics that are able to either cure HBV infection or induce a durable off-drug suppression of the virus, which requires elimination and/or transcriptional silencing of cccDNA, the most stable HBV replication intermediate. We believe that therapeutic regimes with such pharmacological properties are most likely to come in the form of combination therapies with multiple drugs that target different steps of HBV replication. Thus, cccDNA formation can be prevented through more efficient inhibition of nucleocapsid assembly or rcDNA production and conversion to cccDNA, as well as by suppressing the emergence of drug-resistant mutants and accelerating the loss of preformed cccDNA.

To fulfill this goal, we have been developing cell-based assays suitable for the discovery of antiviral drugs that inhibit HBV replication in a high-throughput manner (33, 61, 62).

newchinabok

讨论
慢性乙型肝炎治疗的治疗目标是恢复正常的肝功能，防止肝硬化，肝癌，肝衰竭的发展。它已被证明，到目前为止，现有的抗病毒药物可导致明显的组织学，生化抑制HBV复制，并与肝癌的发病率和死亡率降低血清的改进（60）。然而，目前的抗病毒治疗药物未能解决在绝大多数患者的HBV感染，这些患者的治疗目标的实现需要长期的，可能是终身的，治疗，最终可能导致耐药性和/或不能耐受的出现从长期使用这些药物失败（10）。因此，有疗法能够治愈乙肝病毒感染或诱导持久的病毒抑制药物的迫切需要，这就需要消除和/或转录抑制cccDNA，最稳定的HBV复制中间体。我们相信，这样的药理性质的治疗方案是最有可能来的形式的组合疗法与多药的目标不同的步骤，乙肝病毒复制。因此，cccDNA的形成可以阻止通过更有效的抑制病毒核衣壳组装或生产转换为cccDNA，以及通过抑制耐药突变株的出现和加快预制cccDNA的损失。
为了实现这个目标，我们已经开发了基于细胞的检测适用于高通量的方式，抑制HBV复制的抗病毒药物的发现（33，61，62）。

重韧

阵容很牛B 。

newchinabok

回复 重韧 的帖子

都是老江湖

ivanich

丙肝的攻克者之一，相信他们是最好的！

newchinabok

葛优说的，人才，二十一世纪最缺的是人才。知识，经验都不缺，再需要一些运气